Serum Institute of India Ltd (SIIL), the first body to be commissioned to develop a vaccine against the latest strain of the H1N1 flu virus, is now on the verge of manufacturing the meningococcal A vaccine.
Serum Institute of India Ltd (SIIL), the first body to be commissioned to develop a vaccine against the latest strain of the H1N1 flu virus, is now on the verge of manufacturing the meningococcal A vaccine.
u00a0
|
|
On a Mission: Dr Suresh Jadhav, executive director, SIIL, says they are committed to improving children's health. |
Dr Suresh Jadhav, executive director, SIIL, said, while the meningococcal-A type meningitis is mainly prevalent in Southern Africa, there have been a few outbursts in India as well in the recent past.
"We have applied for the licence of this product to the Drug Controller General of India (DCGI)," Jadhav said.
Vaccines manufactured by the SIIL are supplied to 140 countries in the world either directly or through UN agencies like United Nations International Children and Educational Fund (UNICEF) and Pan American Health Organization (PAHO).
"It is our endeavor to improve the health of the world's children by preventing diseases through immunisation," he said.
